WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Great Elm Group, Inc. (“Great Elm”), (NASDAQ: GEG), today announced plans to host a conference call and webcast to discuss its results for the fiscal quarter ended March 31, 2023, on Friday, May 5, 2023, at 9:00 a.m., ET.
Company to Host Conference Call & Webcast
Great Elm will host a conference call and webcast on Friday, May 5, 2023, at 9:00 a.m. Eastern Time to discuss its fiscal 2023 third quarter financial results.
All interested parties are invited to participate in the conference call by dialing +1 (888) 440-4537; international callers should dial +1 (646) 960-0669. Participants should enter the Conference ID 2595129 when asked.
For a copy of the slide presentation that will be referenced during the conference call, please visit: https://www.greatelmgroup.com/events-and-presentations.
The conference call will be webcast simultaneously and can be accessed at the following link: https://events.q4inc.com/attendee/141685606.
About Great Elm Group, Inc.
Great Elm Group, Inc. (NASDAQ: GEG) is a publicly-traded, alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Great Elm Group, Inc. and its subsidiaries currently manage Great Elm Capital Corp., a publicly-traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments. Great Elm Group, Inc.’s website can be found at www.greatelmgroup.com.
Media & Investor Contact:
Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.87 |
Daily Change: | -0.02 -1.06 |
Daily Volume: | 6,750 |
Market Cap: | US$54.700M |
February 05, 2025 November 11, 2024 February 13, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load